Yazar "Yerlitaş, Serra İlayda" seçeneğine göre listele

Listeleniyor 1 - 2 / 2
  • Küçük Resim Yok
    Öğe
    A Bibliometric and Visual Analysis of Publications on Low-Density Lipoprotein Cholesterol Estimating Equations
    (Sivas Cumhuriyet Üniversitesi, 2024) Bolat, Serkan; Yerlitaş, Serra İlayda; Cephe, Ahu; Koçhan, Necla; Zararsız, Gözde Ertürk; Dogan, Halef Okan; Zararsız, Gökmen
    The concentration of low-density lipoprotein cholesterol (LDL-C) is recognized as a crucial factor in cardiovascular health. This study aims to conduct a comprehensive bibliometric and visual analysis to provide a comprehensive review of current research trends and patterns in this research area. We retrieved the publications from the Web of Science (WoS) database and conducted the bibliometric analyses using VOSviewer software, bibliometrix R package, and biblioshiny web tool. The analysis was conducted on 620 original articles and review papers published between 1990 and 2023 from institutions located in 62 different countries and published in 329 journals. The countries with the most articles were the US, China, and Japan. The most productive journals were Clinica Chemica Acta, Clinical Biochemistry, and Clinical Chemistry; while the most cited journals were Clinical Chemistry, Circulation, and JAMA-Journal of the American Medical Association. The co-occurrence network visualizations of keywords and terms provided a global overview of LDL-C estimating equations. The study presented provides valuable insights into potential research avenues within the examined field, serving as a foundation for future research initiatives.
  • Küçük Resim Yok
    Öğe
    Dysregulated Leukotriene Metabolism in Patients with COVID-19
    (National Institute of Health, 2024) Doğan, Halef Okan; Budak, Mahir; Doğan, Kübra; Zararsız, Gözde Ertürk; Yerlitaş, Serra İlayda; Bolat, Serkan; Şenol, Onur
    This study aimed to examine the leukotriene metabolism during COVID-19. In total, 180 participants were included in this study, of which 60 were healthy controls, 60 required intensive care units (ICU), and 60 did not require intensive care (non-ICU). The serum levels of 5-lipoxygenase (5-LO), 5-LO activating protein (ALOX5AP), and cysteinyl leukotriene (CYSLT) were measured, and the mRNA expression levels of 5-LO, ALOX5AP, and cysteinyl leukotriene receptor 1 (CYSLTR1) were investigated. Compared with the control group, both the non-ICU and ICU groups had lower levels of 5-LO and mRNA expression. ICU patients had lower levels of 5-LO and mRNA expression than non-ICU patients. CYSLTR1 mRNA expression was highest in the ICU group, followed by the non-ICU group, and healthy controls had the lowest mRNA expression levels. CYSLT levels were higher in the control group than in the non-ICU and ICU groups. CYSLTR1 expression was higher in patients than in controls; therefore, selective leukotriene receptor blockers can be used as treatment options. CYSLTR1 expression was higher in the ICU group than in the non-ICU group. Furthermore, CYSLTR1 mRNA expression may be a promising biomarker of COVID-19 severity. © 2024, National Institute of Health. All rights reserved.